|
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical research trials and A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis  A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
For Condition: Multiple Sclerosis
Status: Terminated
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion - relapsing-remitting MS - at least 1 exacerbation in preceding 2 years - at least 1 MRI lesion - stable for 2 months prior to dosing Exclusion - progressive MS - currently treated with an immunomodulatory therapy - previously treated with an approved MS drug where treatment was discontinued for lack of efficacy - active bacterial or viral infections
Total Enrollment:
Location and Contact Information:
Local Institution
New York City, New York,
United States
Local Institution
Dallas, Texas,
United States
Local Institution
Madison, Wisconsin,
United States
Local Institution
New Haven, Connecticut,
United States
Local Institution
Worcester, Massachusetts,
United States
Local Institution
Louisville, Kentucky,
United States
Local Institution
Newark, New Jersey,
United States
Local Institution
Philadelphia, Pennsylvania,
United States
Local Institution
Charlotte, North Carolina,
United States
Local Institution
Burlington, Vermont,
United States
Additional Information:
Study ID Numbers: IM101-200;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035529
Other Multiple Sclerosis Studies:
1. Zenapax to Treat Multiple Sclerosis
2. Combination Therapy with Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
3. Natural Antioxidants in the Treatment of Multiple Sclerosis
4. Safety of RG2077 in Patients With Multiple Sclerosis
5. Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Related Studies:
Other Multiple Sclerosis Clinical Trials
Other New Jersey Clinical Trials
Other Newark Clinical Trials
A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis
|
|
|
|
|
|
|
|
